Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivosRDGL -3.38% FCF Yield % is -7.71 as of Aug. 02, 2026. The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Vivos ranks worse than 69.75% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Vivos's Trailing 12-Month Free Cash Flow is $-2.18 Mil, and Market Cap is $28.34 Mil. Therefore, Vivos's FCF Yield % for today is -7.71%.
The historical rank and industry rank for Vivos's FCF Yield % or its related term are showing as below:
RDGL'
s FCF Yield % Range Over the Past 10 Years
Min: -848.58 Med: -235.75 Max: -7.71
Current: -7.71
During the past 13 years, the highest FCF Yield % of Vivos was -7.71%. The lowest was -848.58%. And the median was -235.75%.
RDGL's FCF Yield % is ranked worse than 69.75% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: -0.42
vs RDGL: -7.71
Vivos's FCF Margin % for the quarter that ended in Mar. 2026 was -1,613.89%.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vivos FCF Yield % Related Terms
Vivos FCF Yield % Historical Data
* Premium members only.
The historical data trend for Vivos's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vivos's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Vivos's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivos (RDGL) has a FCF Yield % of -7.71 as of Aug. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vivos and its competitors. According to the industry distribution chart, Vivos ranks #595 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 69.8%.
Is Vivos' FCF Yield % too high?
Vivos' current FCF Yield % is -7.71. Based on the distribution chart, Vivos ranks #595 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Vivos' FCF Yield % compare to ARAY and FOFA?
According to the Medical Devices & Instruments industry distribution chart, Vivos ranks #595 out of 853 companies for FCF Yield %. This places Vivos in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vivos and its competitors. Vivos's current FCF Yield % is -7.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos stock overvalued right now?
Vivos (RDGL) has a current FCF Yield % of -7.71. The current FCF Yield % is -7.71. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Vivos (RDGL), the current FCF Yield % is -7.71 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDGL has been successfully added to your 
